Scientist-operator bridging life sciences, AI & corporate strategy
PhD in Physical Chemistry (École Normale Supérieure) and an Executive MBA (Collège des Ingénieurs). I translate complex scientific and AI concepts into boardroom execution — advising pharma and biotech on R&D portfolio strategy, diagnostics and go-to-market.
I'm a chemist who ended up in the boardroom. My PhD at the École Normale Supérieure went deep into the physics of reading information out of DNA — but the longer I spent at the bench, the more a different question pulled at me: not just whether a piece of science is good, but whether it is worth building, and how it ever leaves the lab.
So I went and learned the other half. An executive MBA, a deep-tech venture I founded and ran, an organisational transformation inside a global pharma, and now R&D-portfolio strategy at EY-Parthenon — in the room with the people deciding where a billion dollars of research should go. I read a term sheet and a thesis with equal ease.
What I really do is translate: between the wet lab and the boardroom, between what is scientifically true and what is commercially smart. And I build — usually several things at once: an AI platform for biotech investors, models that stress-test pipeline decisions, small tools for whatever problem is in front of me. Based in Paris and originally from Dublin, I am most useful where biology, software and capital meet.
Degrees, roles and ventures on a single timeline — overlapping bars show what ran in parallel. Select any row to read more.
Four-year honours degree in chemical and pharmaceutical sciences, with a research thesis. 2nd Class Honours.
Research masters at the interface of chemistry and biology. Graduated Mention Très Bien — 1st Class Honours.
Led product registrations across 9 South-East Asian countries; advised regulatory affairs officers on compliance requirements.
Recurring one-to-two-month contracts supporting formulation development and EU CLP regulatory classifications — run in parallel with the MSc, PhD and BforCure work.
Co-developed qPCR kits for COVID-19 and respiratory viruses. Oversaw design, installation and regulatory compliance of the chemistry lab; supervised 2 interns.
Executive MBA in Science Management, taken within the Collège des Ingénieurs fellowship — a competitive three-year programme (under 5% admission) that combined the doctorate with rotational placements at leading European firms.
"Innovative Strategies for DNA Analysis using Supramolecular Assemblies and qPCR Multiplexing." Developed high-content PCR (hcPCR) — a multiplexing method that resolves multiple targets per optical channel by deconvolving each probe's temperature–fluorescence signature — and discovered light-based detection of single-point mutations in short DNA sequences.
Investment scout and content/community manager — deal sourcing and community building.
Vice-President of the Collège des Ingénieurs alumni association — building the French alumni community through networking events and TED-talk projects.
Founded a deep-tech biotech venture out of PSL Research University in partnership with a multinational pharmaceutical company. Led company structure, negotiation strategy and market positioning; concluded the venture in 2024 after evaluating commercial viability against alternative paths into strategy consulting.
Founded and built an AI-powered biotech investment-intelligence platform covering 350+ US and EU tickers — parsing SEC filings, tracking FDA/EMA catalysts and generating sentiment scores and daily executive summaries. Also leads the associated investment club.
Project-managed the organisational transformation of 2,400 employees, lifting productivity ~10%. Future-proofed organisational health and improved decision-making structures — a rotational placement within the Collège des Ingénieurs fellowship.
Independently designed and built AuraFast — an AI-driven fasting and metabolic-health tracker with personalised scheduling, on a React/Next.js and Firebase stack.
Acting QMS lead for a large pharmaceutical client; designed strategic frameworks delivering ~20% operational efficiency gains in quality management. Built go-to-market and regulatory strategies for biotech clients in Switzerland, France and Germany.
Selected for a competitive 3-month founder programme. Explored personalised diagnostics, electrochemical biosensors and DNA computing before returning focus to Micromagnetix.
Develop R&D portfolio go-to-market and optimisation strategies for top pharmaceutical clients. Built a Python-based Monte Carlo model for pipeline value and probability-of-success analysis on a $1B+ R&D budget, identifying ~$200M in portfolio efficiency gains.
An analysis from my consulting work, rebuilt as a live tool. Move the sliders — the simulation, chart and key takeaway recompute in real time.
Pharma R&D funds pipelines of mostly-failing assets, where a few winners must pay for the rest. This Monte Carlo model runs 12,000 trial portfolios to stress-test the odds — the same class of analysis behind the EY-Parthenon engagement that surfaced ~$200M in efficiency gains.
My PhD at the École Normale Supérieure (PSL University) — Innovative Strategies for DNA Analysis using Supramolecular Assemblies and qPCR Multiplexing — built new ways to read more information out of a DNA test. I've rebuilt three of its core ideas as interactive models you can explore.
Molecular beacons that capture a short target and chain themselves into a self-assembling supramolecular network.
Explore the model Chapter 3A second melting fingerprint, Tm*, that pulls single-base mutations apart on a two-dimensional map.
Explore the model Chapter 2Reading several targets from a single optical channel by their fluorescence–temperature waveforms.
Explore the modelFrom Dublin to Paris, Munich, and Bern — gaining a pan-European perspective.
Competitive executive-style MBA combining business and leadership training with rotational placements at leading European firms. Admission rate < 5%.
Expertise in analytical physical chemistry, chemical biology, molecular diagnostics and DNA nanotechnology.
Research masters at the interface of chemistry and biology. Mention Très Bien — 1st Class Honours.
Four-year honours degree with a research thesis. 2nd Class Honours.
AI-Powered Biotech Investment Intelligence
An AI-powered biotech investment intelligence platform covering 350+ US and EU tickers. It uses Python and the Google Gemini API to parse SEC filings, track FDA/EMA catalysts, and generate sentiment scores and daily executive summaries for investors.
Intelligent Fasting & Metabolic Health Tracker
A data-driven fasting companion that uses AI to provide personalized health insights. Features include a dynamic fasting timer, metabolic stage tracking, and 'AuraPlan' — an AI scheduler that optimizes weekly fasting goals based on user patterns.
Founder and lead of a biotech investment club with a 30% return rate, driven by systematic technology review and market analysis.
Building the French alumni community of the Collège des Ingénieurs, organizing networking events and TED Talk projects.
Developed an IoT software system for clinical bed management (MIT medical hackathon).
Essays and analysis on biotech strategy, molecular diagnostics, AI and the business of science. A selection below — the full archive, with publications, lives on the articles page.
How supramolecular assemblies are changing the landscape of DNA analysis — and what it means for the next generation of point-of-care testing.
Read article Analysis January 2026An analysis of statistical-arbitrage approaches to clinical-stage biotech catalysts, published on Catalyst Ventures.
Read on Catalyst VenturesI'm based in Paris and open to discussing opportunities in Strategy, Biotech, and Tech.
Email: [email protected]
Phone: +33 6 28 37 04 38